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SHORT COMMUNICATION
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chemotherapeutic agents against Mycobacterium tuberculosis
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Abstract
During the treatment of tuberculosis infection, oxidative stress due to anti-tubercular drugs
may result in tissue inflammation. It was suggested that treatment with antioxidant drugs could
be beneficial as an adjunct to anti-tuberculosis drug therapy. Recently our group has shown
that several C-glycosides are inhibitors of Mycobacterium tuberculosis b-carbonic anhydrases
(CAs, EC 4.2.1.1). In an effort to develop novel chemotherapeutic agents against tuberculosis,
the anti-tubercular and antioxidant activities of a series of C-glycosides containing the phenol
or the methoxyaryl moiety were studied. Many compounds showed inhibition of growth of M.
tuberculosis H37Rv strain and good antioxidant ability. A glycomimetic incorporating the 3-
hydroxyphenyl moiety showed the best activity profile and therefore this functionality
represents lead for the development of novel anti-tubercular agents with dual mechanisms of
action.
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Introduction
Infection with Mycobacterium tuberculosis and related mycobac-
teria affects a large fraction of the world population, with an
estimated 9.4 million new cases and 1.7 million deaths annually1.
Furthermore, tuberculosis (TB) infection including both multi-
drug-resistant tuberculosis (MDR-TB) and drug-resistant tuber-
culosis (XDR-TB) is a leading cause of death worldwide. The
development of novel anti-TB drugs that do not possess cross-
resistance with current anti-mycobacterial drugs and have min-
imal toxicity, is urgently needed due to the increasing incidence of
MDR-TB, XDR-TB and TB-HIV co-infection. In the last 20 years,
the research on M. tuberculosis has made much progress with the
genome deciphered2 and the discovery of possible new drug
targets which may lead to the development of compounds
possessing a novel mechanism of action, thus helping solve the
drug resistance problem mentioned above3,4. Among the new such
proteins identified after the M. tuberculosis genome was
published, there are three b-carbonic anhydrases (CAs, EC
4.2.1.1) which have been cloned, purified and characterized by
Jones’ and Supuran’s groups. Several sulfonamide and sulfamate
inhibitors of the three mycobacterial carbonic anhydrases have
been reported5.
During the treatment of TB infection, oxidative stress may
result in tissue inflammation due to anti-tubercular drugs6.
Recently it has been shown that oxidative stress conditions exist
in the guinea pig model of TB, similar to what is seen in humans.
The systemic and tissue oxidative stress is progressive and
correlates with the loss of Nrf2 mediated antioxidant defense
mechanisms. Considering the importance of lung lesion progres-
sion and the extra-pulmonary dissemination of bacilli in TB
pathogenesis, it was suggested that treatment with antioxidant
drugs could be beneficial as an adjunct to anti-tuberculosis drug
therapy. An added benefit of antioxidant treatment of patients
with TB is the reduction of the toxic side effects of anti-
tuberculosis drug therapy, mediated in part by the generation of
oxygen free radical in the liver7.
These observations led us to propose that the combination of
antioxidant activity and mtCAs inhibition might result in novel
anti-tubercular agents with dual mechanisms of action. Our
strategy towards these dual acting compounds was based on the
synthesis of C-glycosides where the carbohydrate moiety is
tethered to a phenol or methoxyaryl CA pharmacophore through a
carbon chain.
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The replacement of the naturally occurring O-glycoside bond
by C-glycoside bond is an approach practiced in the synthesis of
carbohydrate-containing compounds for the downstream bio-
logical applications8. This isosteric replacement seeks to enhance
stability of the small molecule glycoside toward enzymatic
hydrolysis of the glycosidic bond while retaining vital molecular
recognition interactions with the biological target9.
The use of glycomimetics in the design of carbonic anhydrase
inhibitors (CAIs) has proven to be a successful approach and now
constitutes one of the most attractive ways to develop new
generations of effective and selective inhibitors8,10. Recently one
of our groups has applied the ‘‘sugar approach’’ to the preparation
of C-cinnamoyl phenols, where the carbohydrate moiety is
tethered to a phenol CA pharmacophore through a carbon
chain11. These compounds have been tested as inhibitors of the
Mycobacterium tuberculosis b-CAs and have shown better
inhibitory activity against mtCAs than phenol. Also the anti-
tubercular activity of the C-glycosyl phenols was investigated,
allowing us to identify the first mtCAs inhibitor with antimyco-
bacterial activity12. These glycosides also showed to be very good
inhibitors of Brucella suis CAs13. Very recently we have
developed a novel series of C-glycosides containing the
methoxyaryl scaffold and investigated them as inhibitors against
human and fungal isozymes of carbonic, showing that some of
them are potent and highly selective inhibitors14,15. It should be
pointed out that only very recently methoxyphenyl derivatives
have been investigated as CAIs because it was considered that
they do not bear any moiety normally associated with CA
inhibition in their molecules.
The aim of the present work was to study the anti-tubercular
and antioxidant activity of a series of C-glycosides that could be




C-glycosides 1–20 were previously described and have been
prepared by aldol reaction of aryl aldehydes with per-O-acetylated
Figure 2. Per-O-acetylated C-glycosides (9–14) and fully deprotected derivatives (15–20) containing the methoxyaryl moiety.
Figure 1. Peracetylated C-glycosides (1–4) and fully deprotected derivatives (5–8) containing the phenol moiety.
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C-glucosyl or C-galactosyl ketones and subsequent deprotection
using triethylamine in methanol/water11,14.
Anti-mycobacterial activity assay
Bacterial strains and growth media: Mycobacterium tuberculosis
strain H37Rv was grown in Middlebrook 7H9 broth (Difco
Laboratories, Detroit, MI) supplemented with 1/10 v/v of ADS (a
solution containing 50 g/L BSA fraction V, 20 g/L dextrose and
8.1 g/L NaCl), glycerol (1% w/v) herein designated 7H9-ADS-G
for short. Tween 80 (0.05% w/v) was added to prevent clumping.
When needed, solid media (Middlebrook 7H11) supplemented
with ADS (1/10 v/v) and glycerol (1% v/v) was used. Cultures
were grown at 37 C under gentle agitation.
Stock solutions for all the tested compounds were made in
DMSO at 10 mg/mL. Working solutions were made by dilution in
the above described 7H9-ADS-G medium at a final concentration
of 400 mg/mL.
Antimycobacterial activity was determined by a two-fold
dilution of the compounds in Middlebrook 7H9-ADS-G medium.
For this purpose 96-well plates (Falcon, Cat number 3072,
BectonDickinson, Lincoln Park, NJ) were used. The 96-well
plates received 100mL of Middlebrook 7H9 broth and a serial
two-fold dilution of the compounds was made directly on the
plate. The initial and final drug concentrations tested were 100
and 0.78 mg/mL, respectively. Four compounds were tested in
duplicate in each microtiter plate, Rifampicin (from 2 to 0.16 mg/
mL; stock solution prepared as a 10 mg/mL solution in methanol)
was used as control drug. Two rows were used for growth control
(medium and inoculum alone) and sterility control (medium
alone). The inoculum was prepared as a 1/25 dilution of a fresh
mid-log M. tuberculosis H37Rv suspension (O.D equivalent to Mc
Farland 1.0 scale value) made in Middlebrook 7H9-ADS-G. A
100-mL aliquot (containing approximately 106 Colony Forming
Units) was used to inoculate the wells except for the row used for
sterility testing. Plates were sealed with Parafilm and incubated at
37 C for seven days. Minimum inhibitory concentration (MIC)
was defined as the lowest drug concentration preventing myco-
bacterial growth as judged by visual inspection.
Antioxidant capacity
Stock solutions of the samples were prepared dissolving 15 mg of
the tested compounds in 100mL DMSO (1 mM) and then
homogenizing with absolute methanol until a final volume of
1000mL. The antioxidant capacity (AC) was determined by two
different methods: DPPH and ABTS radical scavenging assays16.
The ABTS assay is based on the ability of samples to quench the
stable cation radical 2,20-azino-bis(3-ethylbenzothiazoline-6-sul-
phonic acid) (ABTS+) with the consequent discoloration of the
blue/green solution when compared to the absorbance of a blank.
Briefly, 10 mL of sample were added to 1 mL ABTS+ working
solution (absorbance of 0.700 ± 0.02 at 734 nm), incubated for
6 min at room temperature and the reduction of absorbance at
734 nm was recorded in a spectrophotometer (Thermo Scientific,
Waltham, MA, Evolution 60S). In the DPPH assay, the capacity of
the sample to reduce the stable and purple radical 2,2-diphenyl-1-
picrylhydrazyl (DPPH) to the yellow-colored diphenylpicrylhy-
drazine was determinated. Aliquots of sample (100 mL) were
added to test tubes containing 150mL of 40 mg/L DPPH ethanolic
solution. The absorbance reduction at 515 nm was measured until
the reaction reached a plateau (60 min). Corresponding blanks
were used to determine the stability of the DPPH solution. For
both assays, Trolox was used as antioxidant standard and results
were expressed as percentage of radical inhibition per 0.1 mg (for
ABTS assay) or 1 mg (for DPPH assay) of tested compounds.
Measures were done in triplicate.
Results and discussion
A set of C-cinnamoyl glycosides (Figures 1 and 2) was
synthesized as outlined in Scheme 1 and described previously
by us11,14. C-cinnamoyl glycosides 1–4 and 9–14 have been
prepared by aldol condensation of b-C-glucosyl and b-C-
galactosyl ketones with aryl aldehydes at room temperature in
the presence of pyrrolidine as catalyst (Scheme 1). The O-acetate
protecting groups of the carbohydrate moiety were next removed
using triethylamine in methanol/water to afford the deprotected
C-glycosides 5–8 and 15–20. All the glycomimetics prepared
have been previously tested against human, bacterial and fungal
CAs and showed very good inhibition profiles11–15. The anti-
tubercular activity of compounds 1–20 was investigated by using
fresh cultures of M. tuberculosis H37Rv grown and tested as
previously described. Tests were carried on by duplicate. Our
results clearly demonstrated that compounds 1, 2, 6, 7 and 10
displayed growth inhibition activity at concentrations between
50 and 100mg/mL (Table 1).
Due to their promising anti-tubercular activity, it was advisable
to evaluate the antioxidant activity of the compounds we
synthesized. We performed DPPH and ABTS radical scavenging
assays as they are the most commonly used methods for screening
antioxidant activities of the various natural as well as synthetic
antioxidants. The results are summarized in Figures 3 and 4.
Scheme 1. Preparation of C-cinnamoyl glycosides 1–20.
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A number of structure–activity relationships (SARs) were
identified in this study and are summarized as follows.
(i) The C-glycosides containing the phenol moiety showed
good radical scavenging activity. Also the glycomimetics
showed better ability compared to the glycosyl ketones used
in their preparation, showing that attaching of the phenyl
moiety improves its scavenging activity. It should be noted
that all deprotected glycomimetics glycosyl exhibited better
activity than the per-O-acetylated derivatives. Galactosides
3 and 7, which possess a hydroxyl group at meta position of
phenyl ring, showed less antioxidant activity as compared to
glucosides 1 and 5, with the same substitution at the
aromatic moiety. A closely related situation was found with
the glycosides containing a –OH at para position of the
phenyl ring, with the exception of compound 8. It is
significant to note that the compounds showing anti-
tubercular activity also showed a moderate to good radical
scavenging activity.
(ii) Some C-glycosides incorporating the methoxyaryl moiety
showed interesting antioxidant activity. In the 6-methox-
ynaphtyl series only derivate 17 showed moderate radical
scavenging activity. Glicosyl derivatives of veratraldehyde
13, 16 and 19 exhibited good antioxidant ability showing
that this moiety could be useful in the design of novel sugar
antioxidants. It is interesting to note that galactoside 10,
Figure 4. Percent inhibition of the ABTS+ radical by tested compounds
(0.1 mg). Standard deviation is shown (n¼ 3).
Figure 3. Percent inhibition of the DPPH radical by tested compounds
(1 mg). Standard deviation is shown (n¼ 3).
Table 1. Anti-tubercular activity of C-glycosides 1–20.
Concentration
Compound 100 mg/mL 50mg/mL 25mg/mL
1* Yesy (++++)z Yes (+++) No
2* Yes (++) Yes (+) No
3* No No No
4* No No No
5* No No No
6* Yes (++) Yes (+) No
7* Yes (++) Yes (+) No
8* No No No
9 No No No
10 Yes (+++) Yes (++) No
11 No No No
12 No No No
13 No No No
14 No No No
15 No No No
16 No No No
17 No No No
18 No No No
19 No No No
20 No No No
*From Reference12.
yYes indicates inhibition of growth, as judged by turbidity.
zExtent of inhibition (+++)4(++)4(+).
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which possesses a very low antioxidant activity, is the only
methoxyaryl derivative that showed anti-tubercular activity.
In conclusion, we have investigated the antioxidant and anti-
tubercular activities of C-glycosides incorporating the phenol or
methoxylaryl moieties. The 3-hydroxyphenyl glycoside (com-
pound 1) exhibited good anti-tubercular and antioxidant activities
showing that this moiety therefore represents a lead for the
development of novel anti-tubercular agents with dual mechan-
isms of action.
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